Skip to Content
Merck
All Photos(1)

Documents

SML2591

Sigma-Aldrich

SCH-39166 hydrobromide

≥98% (HPLC)

Synonym(s):

(-)-trans-6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl- 5H-benzo[d]naptho-(2,1-b)azepine hydrobromide, (6aS,13bR)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide, (6aS-trans)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-Benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide, Ecopipam hydrobromide, PSYRX 101 hydrobromide, PSYRX-101 hydrobromide, PSYRX101 hydrobromide, SCH 39166 hydrobromide, SCH39166 hydrobromide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H20ClNO·HBr
CAS Number:
1227675-51-5
Molecular Weight:
394.73
MDL number:
MFCD08703109
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Biochem/physiol Actions

SCH-39166 (ecopipam) is a high-affinity D1/D5 subtype-selective dopamine receptor antagonist (Ki = 1.2 nM/D1, 2.0 nM/D5, 980 nM/D2, 5.52 μM/D4, 80 nM/5-HT, 731 nM/α2a). SCH-39166 is widely employed both in cultures and in animal studies in vivo.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H336

Hazard Classifications

STOT SE 3

Target Organs

Central nervous system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Brendan D Hare et al.
Nature communications, 10(1), 223-223 (2019-01-16)
Impaired function in the medial prefrontal cortex (mPFC) contributes to depression, and the therapeutic response produced by novel rapid-acting antidepressants such as ketamine are mediated by mPFC activity. The mPFC contains multiple types of pyramidal cells, but it is unclear
Yang Yang et al.
Molecular psychiatry (2018-12-12)
Dopamine D1 agonists enhance cognition, but the role of different signaling pathways (e.g., cAMP or β-arrestin) is unclear. The current study compared 2-methyldihydrexidine and CY208,243, drugs with different degrees of both D1 intrinsic activity and functional selectivity. 2-Methyldihydrexidine is a
Meera E Modi et al.
Frontiers in molecular neuroscience, 11, 107-107 (2018-07-05)
Mutations in the SHANK family of genes have been consistently identified in genetic and genomic screens of autism spectrum disorder (ASD). The functional overlap of SHANK with several other ASD-associated genes suggests synaptic dysfunction as a convergent mechanism of pathophysiology
Takeshi Enomoto et al.
Behavioral neuroscience, 132(6), 526-535 (2018-10-10)
Effort-based decision-making paradigms have recently been used to measure motivation in healthy subjects and patients with neuropsychiatric disorders. In the present study, we developed a novel effort-discounting paradigm using a touch-panel system in common marmosets. Marmosets were trained to choose
M A Tice et al.
Pharmacology, biochemistry, and behavior, 49(3), 567-571 (1994-11-01)
Characterization studies were conducted on the five cloned dopamine receptor subtypes (D1-D5) using the novel D1-selective antagonist, SCH 39166, as well as other related benzazepines and dopaminergic agents. The results demonstrate that SCH 39166 exhibits saturable, high-affinity binding to the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service